Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immuno-bridging study of RSVPreF3 OA vaccine in adults aged 60 years and older
jRCT2031240140Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing RSVPreF3 OA investigational vaccine with Placebo (2 arms). Primary endpoints: RSV-A neutralizing antibody GMT ratio at 1 month, RSV-A seroresponse rate difference at 1 month and 2 more. Started Aug 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031240140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240140.